REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN)

Historical Holders from Q1 2014 to Q4 2025

Type / Class: Equity / COMMON STOCK
Symbol: REGN on Nasdaq
Shares outstanding: 104,986,330
Price per share: $771.87
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares as of 30 Sep 2025: 86,922,112
Total reported value: $48,893,674,176
% of total 13F portfolios: 0.03%
Share change: -2,265,719
Value change: -$1,217,117,620
Avg buy value change: +0.01%
Avg sell value change: -0.01%
Number of holders: 1,225
Price from insider filings: $800.00

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
JPMORGAN CHASE & CO	4.4%	-14%	$2,729,989,170	-$462,704,633	4,742,611	-14%	JPMORGAN CHASE & CO.	30 May 2025
FMR LLC	3.2%	-55%	$1,933,864,996	-$2,779,837,001	3,359,563	-59%	FMR LLC	30 Jun 2025

As of 30 Sep 2025, REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN) has 1,225 institutional shareholders filing 13F forms. They hold 86,922,112 shares. of 104,986,330 outstanding shares (83%) .

Top 25 institutional shareholders own 54% of the company.

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
VANGUARD GROUP INC	8.6%	9,048,269	-4%	0.08%	$5,087,570,211
BlackRock, Inc.	8.4%	8,837,174	-4.7%	0.09%	$4,968,878,140
STATE STREET CORP	4.5%	4,691,223	-2.9%	0.09%	$2,637,733,956
Dodge & Cox	4.3%	4,550,845	+19%	1.4%	$2,558,803,618
JPMORGAN CHASE & CO	3.9%	4,072,326	+3.4%	0.15%	$2,289,760,415
GEODE CAPITAL MANAGEMENT, LLC	2.4%	2,535,898	+2.9%	0.09%	$1,419,627,369
FRANKLIN RESOURCES INC	2.3%	2,453,143	+6%	0.35%	$1,379,328,713
Capital World Investors	1.9%	1,998,366	+1.6%	0.15%	$1,123,608,855
LOOMIS SAYLES & CO L P	1.9%	1,979,453	+2%	1.3%	$1,112,987,056
FMR LLC	1.8%	1,935,835	-42%	0.06%	$1,088,462,214
Invesco Ltd.	1.4%	1,484,473	+38%	0.13%	$834,674,573
MORGAN STANLEY	1.4%	1,450,972	+13%	0.05%	$815,840,196
Nuveen, LLC	1.1%	1,175,277	+40%	0.17%	$660,822,999
BANK OF AMERICA CORP /DE/	1.1%	1,153,933	-5.4%	0.05%	$648,821,756
NORTHERN TRUST CORP	0.94%	984,792	+2.7%	0.07%	$553,718,997
GOLDMAN SACHS GROUP INC	0.91%	952,839	+20%	0.08%	$535,752,949
TWO SIGMA ADVISERS, LP	0.88%	926,200	-1.3%	1%	$520,774,474
Capital International Investors	0.83%	876,564	-72%	0.08%	$492,851,584
D. E. Shaw & Co., Inc.	0.82%	861,593	+11%	0.39%	$484,447,896
PRICE T ROWE ASSOCIATES INC /MD/	0.77%	804,910	+5%	0.05%	$452,578,000
Legal & General Group Plc	0.73%	770,359	+4.2%	0.1%	$433,149,757
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.72%	755,565	+4.9%	0.07%	$424,831,533
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC	0.71%	744,173	-14%	0.09%	$418,426,152
AQR CAPITAL MANAGEMENT LLC	0.69%	721,354	+529%	0.26%	$405,595,821
DEUTSCHE BANK AG\	0.66%	696,681	-2%	0.13%	$391,722,827

Institutional Holders of REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (% of par)	Investors
2025 Q4	709,151	$547,333,914	-$28,745,225			77,187%	60
2025 Q3	86,922,112	$48,893,674,176	-$1,217,117,620	$890,604,882	$1,354,111,469	56,227%	1,225
2025 Q2	89,209,869	$46,858,212,368	-$1,426,702,161	$891,077,204	$1,031,185,485	52,500%	1,192
2025 Q1	91,953,296	$58,281,540,993	-$1,190,545,250	$883,151,254	$872,295,968	63,423%	1,271
2024 Q4	93,003,966	$66,292,875,044	+$312,411,528	$980,104,285	$1,080,401,248	71,233%	1,286
2024 Q3	91,369,529	$95,849,165,939	-$2,790,889,009	$1,582,219,661	$1,281,291,825	105,124%	1,365
2024 Q2	93,931,197	$98,688,716,978	+$2,504,344,607	$1,357,989,745	$950,660,212	105,103%	1,315
2024 Q1	91,558,421	$88,000,702,452	+$1,166,274,881	$1,409,151,548	$800,674,923	96,249%	1,293
2023 Q4	729,638	$641,009,482	-$145,675,694			87,829%	17
2023 Q3	89,932,366	$74,022,797,461	-$573,165,604	$1,360,515,087	$1,253,926,827	82,296%	1,149
2023 Q2	90,747,690	$65,274,231,910	-$2,750,858,930	$1,375,655,620	$1,191,019,132	71,854%	1,138
2023 Q1	90,384,111	$74,219,149,328	-$1,223,946,196	$1,711,282,588	$1,554,312,772	82,167%	1,158
2022 Q4	91,259,426	$65,828,079,390	-$200,302,784	$1,392,249,257	$1,061,813,107	72,149%	1,127
2022 Q3	91,689,090	$63,201,513,150	-$159,913,856	$1,338,956,500	$1,030,993,463	68,887%	1,043
2022 Q2	92,956,330	$54,930,158,972	+$596,089,818	$783,017,500	$531,795,000	59,113%	1,037
2022 Q1	82,170,454	$57,370,125,075	+$1,529,724,018	$1,065,226,932	$639,690,718	69,841.97%	1,061
2021 Q4	69,921,237	$44,127,182,246	+$441,749,897	$1,359,217,000	$855,771,000	63,152%	1,047
2021 Q3	69,491,728	$42,013,552,560	+$478,267,410	$1,355,536,000	$1,040,169,000	60,517.99%	991
2021 Q2	79,727,291	$44,477,094,257	-$28,924,360	$1,156,900,000	$906,113,000	55,853.96%	947
2021 Q1	89,362,407	$42,245,647,798	-$352,691,727	$1,326,827,000	$840,337,796	47,313.8%	902
2020 Q4	89,468,967	$43,176,601,269	-$836,292,760	$1,157,827,608	$871,126,830	48,310.85%	879
2020 Q3	89,812,777	$50,283,258,601	-$626,633,279	$879,180,000	$843,570,000	55,978.01%	888
2020 Q2	90,646,424	$56,512,811,066	+$10,659,071,473	$969,143,975	$1,004,933,000	62,364.9%	912
2020 Q1	73,839,990	$36,044,844,177	+$991,849,560	$863,671,006	$942,554,030	48,828.98%	786
2019 Q4	73,130,739	$27,455,902,850	+$184,251,756	$792,779,000	$677,892,000	37,547.99%	677
2019 Q3	72,804,983	$20,195,823,274	-$56,972,585	$489,029,000	$455,180,000	27,740%	603
2019 Q2	73,582,846	$23,022,199,854	+$181,006,352	$566,536,000	$456,886,000	31,300%	640
2019 Q1	72,413,136	$29,714,550,713	-$48,442,835	$727,325,000	$473,584,000	41,061.9%	692
2018 Q4	73,028,151	$27,275,544,609	-$163,089,694	$741,241,000	$654,236,000	37,349.89%	648
2018 Q3	73,300,653	$29,613,843,634	+$479,311,958	$885,364,000	$695,528,000	40,403.63%	623
2018 Q2	72,229,620	$24,917,010,854	+$363,477,996	$641,613,088	$509,511,007	34,498.89%	602
2018 Q1	71,966,803	$24,777,574,861	+$206,772,482	$774,772,701	$557,860,058	34,435.89%	601
2017 Q4	71,108,267	$26,733,454,598	-$475,891,788	$1,139,030,623	$1,199,462,799	37,595.99%	617
2017 Q3	71,864,949	$32,130,149,743	-$383,636,432	$1,077,471,113	$939,340,025	44,711.93%	590
2017 Q2	72,633,782	$35,667,988,549	+$1,276,921,411	$1,293,366,056	$1,283,332,182	49,113.97%	585
2017 Q1	71,473,047	$27,694,183,545	+$2,456,692,713	$719,902,145	$703,589,087	38,750.98%	564
2016 Q4	71,758,870	$26,343,584,723	-$644,622,147	$637,593,112	$698,184,006	36,708.99%	564
2016 Q3	72,762,550	$29,238,474,482	+$503,682,119	$678,917,000	$602,513,000	40,201.83%	543
2016 Q2	71,618,478	$25,024,959,783	-$370,198,371	$482,744,000	$527,815,000	34,922.93%	531
2016 Q1	71,675,066	$25,835,562,007	-$143,426,414	$385,030,000	$394,705,000	36,043.96%	536
2015 Q4	72,777,366	$39,508,716,129	-$22,629,662	$791,959,000	$545,744,000	54,286.87%	566
2015 Q3	73,042,929	$33,974,644,264	-$196,729,040	$722,830,000	$488,392,000	46,514%	550
2015 Q2	72,858,532	$37,169,648,718	+$405,385,955	$724,252,000	$520,729,000	51,012.77%	531
2015 Q1	72,952,735	$32,932,257,708	+$440,864,535	$620,094,000	$411,629,000	45,147.98%	502
2014 Q4	72,035,196	$29,553,171,522	+$117,753,889	$667,428,000	$500,233,000	41,024.96%	504
2014 Q3	71,645,929	$25,825,991,495	-$604,937,030	$438,718,000	$286,212,000	36,051.94%	470
2014 Q2	73,368,344	$20,726,843,276	-$13,507,747	$344,398,000	$196,990,000	28,246.98%	444
2014 Q1	73,402,366	$22,037,080,841	-$740,903,044	$381,913,000	$271,145,000	30,027.95%	448